SEARCH

SEARCH BY CITATION

Abstract

  1. Top of page
  2. Abstract
  3. Materials and Methods
  4. Results
  5. Discussion
  6. Acknowledgements
  7. References

Glycerol phenylbutyrate is under development for treatment of urea cycle disorders (UCDs), rare inherited metabolic disorders manifested by hyperammonemia and neurological impairment. We report the results of a pivotal Phase 3, randomized, double-blind, crossover trial comparing ammonia control, assessed as 24-hour area under the curve (NH3-AUC0-24hr), and pharmacokinetics during treatment with glycerol phenylbutyrate versus sodium phenylbutyrate (NaPBA) in adult UCD patients and the combined results of four studies involving short- and long-term glycerol phenylbutyrate treatment of UCD patients ages 6 and above. Glycerol phenylbutyrate was noninferior to NaPBA with respect to ammonia control in the pivotal study, with mean (standard deviation, SD) NH3-AUC0-24hr of 866 (661) versus 977 (865) μmol·h/L for glycerol phenylbutyrate and NaPBA, respectively. Among 65 adult and pediatric patients completing three similarly designed short-term comparisons of glycerol phenylbutyrate versus NaPBA, NH3-AUC0-24hr was directionally lower on glycerol phenylbutyrate in each study, similar among all subgroups, and significantly lower (P < 0.05) in the pooled analysis, as was plasma glutamine. The 24-hour ammonia profiles were consistent with the slow-release behavior of glycerol phenylbutyrate and better overnight ammonia control. During 12 months of open-label glycerol phenylbutyrate treatment, average ammonia was normal in adult and pediatric patients and executive function among pediatric patients, including behavioral regulation, goal setting, planning, and self-monitoring, was significantly improved. Conclusion: Glycerol phenylbutyrate exhibits favorable pharmacokinetics and ammonia control relative to NaPBA in UCD patients, and long-term glycerol phenylbutyrate treatment in pediatric UCD patients was associated with improved executive function (ClinicalTrials.gov NCT00551200, NCT00947544, NCT00992459, NCT00947297). (HEPATOLOGY 2012)

Urea cycle disorders (UCD) are rare inborn errors of metabolism which result from mutations in the genes encoding for one of six enzymes or two transporters necessary for normal function of the urea cycle and are characterized by hyperammonemia and life-threatening hyperammonemic crises.1, 2 Hyperammonemia-related neurologic injury ranges from lethal cerebral edema to mild or subclinical cognitive impairment among individuals with milder genetic defects.3 Abnormalities in executive function manifested by difficulty in goal setting, planning, monitoring progress, and purposeful problem solving significantly impair day-to-day functioning among children with UCDs, even in those with milder disease who present beyond the neonatal period.4

Management of UCD patients typically involves dietary protein restriction, dietary supplements, and when dietary management alone is insufficient, sodium phenylbutyrate (NaPBA), the only approved drug (Ucyclyd Pharma, U.S. trade name: Buphenyl, EU: Ammonaps) for treatment of UCDs.2, 5 Glycerol phenylbutyrate is an investigational agent being developed for UCDs.6-8 Like NaPBA, it contains phenylbutyric acid (PBA), a prodrug that is converted by way of β-oxidation to the active moiety, phenylacetic acid (PAA), which conjugates with glutamine to form phenylacetylglutamine (PAGN). PAGN is excreted in the urine and mediates waste nitrogen excretion. Unlike NaPBA, glycerol phenylbutyrate consists of three molecules of PBA joined to glycerol in ester linkage that is hydrolyzed in the small intestine by pancreatic lipases to release PBA, contains no sodium, has minimal taste and no odor, and 17.4 mL of glycerol phenylbutyrate contains the same amount of PBA as 40 tablets of NaPBA, the maximal approved daily dose.6, 7, 8

The development of glycerol phenylbutyrate for UCD, rare disorders with fewer than 500 patients currently estimated to be treated with NaPBA in the U.S., has involved a cooperative effort among investigators of the NIH-funded UCD Consortium, the National Urea Cycle Disorders Foundation and Hyperion Therapeutics.2, 9, 10 This report describes the results of the pivotal Phase 3 study of glycerol phenylbutyrate for UCD, as well as short- and long-term ammonia control and neurocognitive outcomes among a total of 91 UCD patients participating in four clinical trials.

Materials and Methods

  1. Top of page
  2. Abstract
  3. Materials and Methods
  4. Results
  5. Discussion
  6. Acknowledgements
  7. References

Trial Design.

The pivotal study (HPN-100-006) was conducted under a Special Protocol Agreement with the U.S. Food and Drug Administration (FDA) and approved by Health Canada. The study was a randomized, double-blind, double-dummy, active-controlled, crossover study to test the hypothesis that glycerol phenylbutyrate is noninferior to NaPBA with respect to blood ammonia control. The protocol-specified sample size of 44 was based on the number required to achieve 90% power to demonstrate noninferiority, assuming equivalent ammonia control for glycerol phenylbutyrate and NaPBA. Secondary objectives were to assess safety and pharmacokinetics; plasma glutamine was analyzed post-hoc. Adult UCD patients with UCD subtypes including deficiencies of carbamoyl-phosphate synthetase (CPS1), ornithine transcarbamylase (OTC), and argininosuccinate synthetase (ASS1) on maintenance therapy with NaPBA were enrolled.

Patients were randomized equally in accordance with a computer-generated central randomization schedule to receive placebo glycerol phenylbutyrate plus active NaPBA or placebo NaPBA plus active glycerol phenylbutyrate for 14 days and then crossed over to receive the alternate treatment. All investigators and study personnel, including the site pharmacist, were blinded to the study drug assignment. The dose of glycerol phenylbutyrate was calculated to deliver the same amount of PBA as each patient's baseline NaPBA dose. Therefore, regardless of treatment, patients received the same amount of PBA throughout the study and followed a stable diet in terms of protein and calorie intake. At the end of each treatment period, patients underwent repeated blood sampling over 24 hours in a monitored clinical setting for NH3 and plasma and urine levels of metabolites, including PBA, PAA, and PAGN. The primary efficacy measure was daily ammonia exposure, assessed as 24-hour area under the curve (NH3-AUC0-24hr), which was natural log-transformed and analyzed using an analysis of variance. Noninferiority was to be achieved if the upper 95% confidence interval (CI) for the ratio of the least squares means between glycerol phenylbutyrate and NaPBA was less than or equal to 1.25. The noninferiority margin of 1.25 is consistent with FDA guidance on bioequivalence studies and corresponds to an absolute difference of ∼ 9 μmol/L for a patient with an ammonia at the upper limit of normal (35 μmol/L), a clinically insignificant change.

Protocols UP 1204-003 and HPN-100-005, the results of which have been previously reported, were open-label, fixed-sequence, NaPBA to glycerol phenylbutyrate switch-over studies in adult (n = 10) and pediatric patients (n = 11), respectively, on maintenance therapy with NaPBA.6, 8 The duration of dosing for each treatment was 7 days, after which patients underwent 24-hour ammonia and PK sample collection similar to the pivotal study.

Patients completing studies HPN-100-005 and HPN-100-006 were offered enrollment into one of two 12-month glycerol phenylbutyrate treatment protocols (HPN-100-005SE, HPN-100-007), which required monthly visits that included measurement of fasting ammonia. These protocols also allowed for enrollment of adult and pediatric UCD patients, including all UCD subtypes, who had not completed HPN-100-005 or HPN-100-006. The results of these studies are included for the purposes of pooled analyses.

All patients underwent neuropsychological testing at the time of enrollment in HPN-100-005SE or HPN-100-007 and again at study completion. All patients were administered a short form of the WASI (Wechsler Abbreviated Scale of Intelligence) to estimate intellectual ability. Pediatric patients were also assessed by two parent questionnaires: the CBCL (Child Behavior Checklist) to evaluate internalizing (e.g., mood/anxiety) and externalizing behaviors and the BRIEF (Behavior Rating Inventory of Executive Function) to assess day-to-day executive functioning. The BRIEF consists of several subscales that are combined into two functional domains; the Metacognition Index (MI), which measures cognitive control (e.g., working memory, planning, organization, etc.) and the Behavioral Regulation Index (BRI), which measures behavioral control (e.g., inhibition, flexibility, emotional control). In addition to WASI, adults were administered the Lafayette Grooved Pegboard test (fine motor skills), California Verbal Learning Test-Second Edition (verbal memory), and digit span test (focused attention and working memory).

Hyperammonemic crises were prospectively defined in all protocols as requiring at least one ammonia value over 100 μmol/L plus clinical manifestations compatible with hyperammonemia.

All protocols were conducted under a U.S. IND and were reviewed and approved by the appropriate Institutional Review Board. A Data Safety Monitoring Board was engaged throughout the studies and reviewed all safety results periodically. All patients or their parents signed a consent or assent form, which had been approved by local Institutional Review Boards prior to enrollment and initiation of any protocol-specific activities.

Results

  1. Top of page
  2. Abstract
  3. Materials and Methods
  4. Results
  5. Discussion
  6. Acknowledgements
  7. References

Pivotal Study (HPN-100-006).

Forty-six patients were enrolled; 45 received at least one dose of study drug and 44 completed the study and constituted the intention to treat (ITT) population (Table 1). Enrollment began in October of 2009 and follow-up of the last patient was completed in September of 2010. Overall treatment compliance was excellent, with ≥99% of patients being at least 80% compliant with the NaPBA and glycerol phenylbutyrate treatments. The predominance of patients with OTC deficiency in the pivotal study, as well as the entire study population, is generally consistent with the predominance of this UCD subtype in the population at large.9, 10, 14 Patients had been taking an average of 14.54 g/day of NaPBA for an average of ∼ 11 years at enrollment.

Table 1. Patient Demographics and Disposition
Protocol Number (Safety Population)UP 1204-003 (N = 14)HPN-100-005 (N = 11)HPN-100-006 (N = 45)HPN-100-005 SE HPN-100-007 (N = 77)
DesignPhase 2, open-label, fixed-sequence, switch-overPhase 2, open-label, fixed-sequence, switchoverPhase 3, randomized, double-blind, active-controlled, crossover12-month open label safety studies
  1. ARG1 = arginase deficiency; ASS1 = argininosuccinate synthase deficiency; ASL = argininosuccinate lyase deficiency; CPS1 = carbamoyl-phosphate synthetase 1 deficiency; HHH = ornithine translocase deficiency; OTC = ornithine transcarbamylase deficiency; SD = standard deviation; UCD = urea cycle disorder; NaPBA = sodium phenylbutyrate (BUPHENYL); GPB = glycerol phenylbutyrate; PBA = phenylbutyric acid; HA = Hyperammonemic Crisis; NA = not applicable.

Sex, n (%)Male5 (35.7)1 (9.1)14 (31.1)22 (28.6)
Female9 (64.3)10 (90.9)31 (68.9)55 (71.4)
Age (years) at screening visitMean (SD)35.71 (16.3)10.18 (3.9)32.73 (13.5)24.68 (14.7)
Median30.0010.0028.0022.00
UCD Subtype n (%)OTC12 (85.7)9 (81.8)40 (88.9)63 (81.8)
CPS 1002 (4.4)1 (1.3)
ARG1001 (1.3)
ASS11 (7.1)1 (9.1)3 (6.7)6 (7.8)
ASL01 (9.1)3 (3.9)
HHH1 (7.1)03 (3.9)
Age at Diagnosis n (%)<2 yrs old4 (28.6)6 (54.5)10 (22.2)26 (33.8)
>2 yrs old10 (71.4)5 (45.5)35 (77.7)51 (66.2)
Daily dose of NaPBA prior to study (g)Mean (SD)13.49 (6.075)12.41 (4.392)14.54 (6.808)NA
Median12.7810.5015.00NA
Duration of NaPBA Treatment (mo)Mean (SD)97.89 (88.4)74.68 (48.2)128.57 (97.4)NA
Median84.0076.0120.00NA
HA crises within 12 months before enrollment, n (%)Crises871824
Patients With ≥ 1 crisis6 (42.9%)4 (36.4)9 (20.0)15 (19.5)
Dose during study (grams of PBA/day)NaPBA12.22 (4.048)10.90 (3.858)12.33 (5.582)NA
GPB12.36 (3.917)11.10 (3.805)12.50 (5.529)11.84 (5.179)
Completed the protocolNA10114469
Continued in Safety Extension StudiesNANA1140NA

NH3 values on both drugs were lowest after overnight fasting and peaked postprandially. The primary endpoint was achieved; the lower and upper 95% CIs for the ratio of NH3-AUC24hr on glycerol phenylbutyrate relative to NaPBA in the ITT population were 0.799 and 1.034, respectively (Table 2). Irrespective of treatment sequence, plasma glutamine values were lower during treatment with glycerol phenylbutyrate as compared with NaPBA (mean [SD] of 761.2 [243.2] versus 805.5 [246.6] μmol/L; upper limit of normal [ULN] = 746 [P = 0.064 by paired t test and P = 0.048 by Wilcoxon signed-rank test]) (Table 2).

Table 2. Blood Ammonia, Plasma Glutamine, and Urinary Excretion of Phenylacetylglutamine (PAGN)
 Across StudiesPooled Primary Efficacy Analysis
UP 1204-003HPN-100-005HPN-100-006
  • AUC = area under the curve; CI = confidence interval; GPB = glycerol phenylbutyrate; ITT = intent-to-treat; NaPBA = sodium phenylbutyrate; SD = standard deviation; CV% = coefficient of variation; PBA = phenylbutyric acid; PAGN = phenylacetylglutamine.

  • *

    Results on original scale were obtained by exponentiating the corresponding log-transformed results.

  • P-value obtained from a paired t-test

  • P-value obtained from a Wilcoxon signed-rank test

  • §

    % of PBA recovered in urine as PAGN

  • ||

    % of total urinary PAGN excretion occurring from 0-12 or 12-24 hours

  • NA: Not available.

N10114465
Blood ammonia AUC0-24 (μmol·h/L)
Mean (SD)NaPBA1303.5 (1082.25)813.5 (322.11)976.6 (865.35)1008.4 (849.50)
GPB724.0 (314.95)602.2 (188.09)865.9 (660.53)799.4 (568.53)
Ratio of geometric means *0.630.780.910.84
95% CI* (0.361, 1.116)(0.556, 1.095)(0.799, 1.034) (0.739, 0.962)
P-value0.0750.0470.2110.016
P-value0.0840.0540.3150.013
Plasma glutamine (μmol/L)   
Mean (SD)NaPBA815.2 (315.64)725.1 (204.17)805.5 (246.60)792.7 (247.26)
GPB751.0 (410.52)650.3 (187.33)761.2 (243.20)740.7 (262.82)
P-value0.2190.0960.0640.006
P-value0.1560.0830.0480.004
Urinary PAGN excretion
Mean (CV%) (g) 0-24 hrNaPBA12.2 (48.2)12.5 (51.3)13.6 (52.0)NA
GPB10.8 (25.9)12.5 (56.9)13.5 (52.5)NA
Mean recovery of PBA as PAGN§NaPBA54%69 %71%71%
GBP54%66 %69%68%
% excreted from 0-12 hr ||NaPBA61%57%60%NA
GPB50%45%52%NA
% excreted from 12-24 hr ||NaPBA39%43%40%NA
GBP50%55%48%NA

Adverse events (AEs) on study were reported by 61% and 51% of patients during glycerol phenylbutyrate and NaPBA treatment, respectively, with most being gastrointestinal (GI) and generally mild. Symptoms suggestive of GI disorders, irrespective of treatment, included diarrhea, flatulence, abdominal discomfort, dyspepsia, nausea, vomiting, and oral discomfort. No clinically significant laboratory or electrocardiogram (ECG) changes were observed. One patient experienced a hyperammonemic crisis and one withdrew early because of high NH3 and headache; both during NaPBA treatment. One patient had an SAE of gastroenteritis on glycerol phenylbutyrate. There were no deaths during the study.

As compared with NaPBA treatment, 24-hour AUC and peak plasma metabolite levels in the pivotal study tended to be lower on glycerol phenylbutyrate (PBA = 433 versus 508 μg·h/mL, PAA = 447 versus 599 μg·h/mL, PAGN = 1,127 versus 1,252 μg·h/mL) and trough values higher (PBA = 1.44 versus 0.0905 μg/mL; PAA = 2.11 versus 0.903 μg/mL; PAGN = 15.1 versus 9.09 μg/mL). Twenty-four hour urinary PAGN output was very similar (69% to 71% of PBA dose excreted as urinary PAGN for glycerol phenylbutyrate and NaPBA, respectively), but with a greater proportion of urinary PAGN excreted overnight (i.e., from 12-24 hours) on glycerol phenylbutyrate as compared to NaPBA (Table 2).

Pooled Analysis: Short-Term Ammonia Control and Glutamine.

The individual and pooled analyses of NH3-AUC0-24hr of protocols HPN-100-006, UP 1204-003, and HPN-100-005 are summarized in Table 2 and depicted in the left panel of Fig. 1. Each study showed noninferiority of glycerol phenylbutyrate to NaPBA and directionally lower ammonia values during glycerol phenylbutyrate treatment, a difference that was statistically significant in the pooled analysis (P < 0.05). The analysis of noninferiority was consistent among the subpopulations examined, including age (6-17, ≥18 years), sex (male, female), UCD type (OTC, non-OTC), and age at onset of UCD symptoms (≤2, >2 years) (Fig. 2).

thumbnail image

Figure 1. Short- and long-term blood ammonia levels in UCD patients. This figure depicts the pooled results of ammonia control during short-term (2 to 4 week) treatment with sodium phenylbutyrate (NaPBA) or glycerol phenylbutyrate (GPB) (left panel) as well as of long-term (up to 1 year) treatment with glycerol phenylbutyrate (right panel). The vertical bars represent standard error (SE). All ammonia values were normalized to a standard range of 9-35 μmol/L, and the numbers at the bottom of the right panel indicate the number of patients for whom data were available at each timepoint.

Download figure to PowerPoint

thumbnail image

Figure 2. Pooled analysis of blood ammonia across subpopulations. The ratio of geometric means for blood ammonia, assessed as 24-hour AUC, during treatment with glycerol phenylbutyrate relative to treatment with NaPBA is depicted along with respective upper and lower 95% CIs. An upper 95% CI of less than 1.25 was prespecified as demonstrating noninferiority. An upper 95% CI of less than 1.0 was prespecified as indicating superiority.

Download figure to PowerPoint

Blood glutamine levels were non-significantly lower on glycerol phenylbutyrate in both Phase 2 studies and were significantly lower on glycerol phenylbutyrate than NaPBA in the pooled analysis with a mean (SD) of 740.7 (262.8) versus 792.7 (247.3) μmol/L (P = 0.006 paired t test; P = 0.004 Wilcoxon signed-rank test).

In the pooled analysis the most frequently reported AEs with glycerol phenylbutyrate and NaPBA were GI disorders (32.3% and 25.7%) followed by nervous system disorders (12.3% and 15.7%). Common AEs reported by at least 10% of patients during glycerol phenylbutyrate treatment included diarrhea, flatulence, and headache, and with NaPBA treatment, nausea.

Long-Term Treatment.

Forty patients who completed HPN-100-006 and 11 who completed HPN-100-005 enrolled in the long-term protocols; 26 additional adult and pediatric patients were also enrolled in the long-term protocol for a total of 77 UCD patients (51 adult and 26 pediatric patients ages 6-17, collectively including ARG1, ASL, ASS1, CPS1, HHH, and OTC, subtypes) (Fig. 3). Mean ammonia values during long-term treatment with glycerol phenylbutyrate were similar to the mean fasting values (time 0 or 24 hours) observed during the short-term controlled studies and well below the ULN (35 μmol/L) for both pediatric and adult patients at each monthly visit, with monthly means approximately half the ULN and ranging from 6.3 (month 9) to 29.6 μmol/L (month 11) (Fig. 1).

thumbnail image

Figure 3. UCD patient disposition. Forty of 44 patients completing protocol HPN-100-006 enrolled in the 12-month safety protocol, HPN-100-007, in addition to 11 adult and 9 pediatric patients, for a total of 60. All patients completing the switchover part of protocol HPN-100-005 entered the safety extension of this protocol, HPN-100-005SE, along with nine additional pediatric patients who enrolled directly into HPN-100-005SE. Of the 77 patients total who enrolled in either HPN-100-007 or HPN-100-005SE, 69 completed, including 45 adult and 24 pediatric patients.

Download figure to PowerPoint

Common AEs reported in at least 10% of patients during long-term treatment included vomiting, upper respiratory tract infection, nausea, nasopharyngitis, diarrhea, headache, hyperammonemia, decreased appetite, cough, fatigue, dizziness, and oropharyngeal pain. Only two AEs, hyperammonemia and dizziness, were reported that had not previously been reported with short-term treatment.

Fifteen patients reported 24 hyperammonemic crises in the 12 months preceding enrollment during treatment with sodium phenylbutyrate, whereas 12 patients experienced 15 crises while being treated with GPB on study. As compared with the prior hyperammonemic crises, those during glycerol phenylbutyrate treatment tended to be associated with lower ammonia values at admission, at peak, and at discharge (143.86 versus 171.04 μmol/L, 167.57 versus 183.55 μmol/L, and 35.67 versus 42.41 μmol/L, respectively).

All neuropsychological test results remained stable in adults, as did WASI and CBCL scores in pediatric patients. Most BRIEF subscales at baseline among pediatric patients were at or close to a T score of 65, consistent with borderline and/or clinically significant dysfunction.11 The T scores of 50 with a standard deviation of 10 are considered normative means for all BRIEF clinical scales, and T score of 65 is generally considered clinically significant executive dysfunction.4 Among 22 pediatric patients who completed the neuropsychological testing after 12 months (Fig. 4), all BRIEF domains were significantly improved with means (SD) at the end of the study as compared to baseline for the Behavioral Regulation Index 53.7 (9.8) versus 60.4 (14.0) (P = 0.028); Metacognition Index 57.5 (9.8) versus 67.5 (13.7) (P < 0.001); and Global Executive Scale 56.5 (9.7) versus 66.2 (14.0) (P < 0.001).

thumbnail image

Figure 4. BRIEF domain T scores in pediatric patients (6-17 years) treated with glycerol phenylbutyrate for 12 months. Scores are shown at baseline (gray symbols) and at the end of 12 months of glycerol phenylbutyrate treatment (black symbols) for pediatric patients ages 6-17. The T scores of 50 with an SD of 10 are considered normative means for all BRIEF clinical scales, and a T score of 65 is generally considered clinically significant executive dysfunction.4 An asterisk indicates statistically significant improvement (*P < 0.05). BRIEF stands for Behavior Rating Inventory of Executive Function.

Download figure to PowerPoint

Discussion

  1. Top of page
  2. Abstract
  3. Materials and Methods
  4. Results
  5. Discussion
  6. Acknowledgements
  7. References

The 91 UCD patients enrolled in the trials reported here collectively correspond to ∼ 20% of all UCD patients in the U.S. who are currently estimated to be treated with NaPBA. In the pivotal study, glycerol phenylbutyrate met its predefined endpoint of noninferiority to NaPBA with respect to ammonia control, assessed as NH3-AUC0–24hr. Consistent with the results of each of the prior two Phase 2 studies, NH3-AUC0–24hr was directionally lower during treatment with glycerol phenylbutyrate and the 24-hour profiles for both blood ammonia concentration and U-PAGN excretion were consistent with slow release behavior of glycerol phenylbutyrate.6, 8

Similarities in study design (e.g., study population, efficacy measures, analytical approach) and dosing (PBA mole-equivalent doses of NaPBA and HPN-100) among protocols UP 1204-003, HPN-100-005, and HPN-100-006 allowed for pooling of data from these studies. In the pooled analysis, NH3-AUC0–24hr was significantly lower during treatment with glycerol phenylbutyrate, a difference that was entirely attributable to better control during late afternoon and overnight hours, when UCD patients might be expected to be particularly vulnerable. These findings were consistent among all predefined subgroups. Furthermore, mean blood ammonia levels remained within the normal range for up to 12 months in both adult and pediatric patients.

Glutamine also tended to be lower on glycerol phenylbutyrate as compared with NaPBA by post-hoc analyses in each study individually and was significantly lower in the pooled analysis. Glutamine not only represents a precursor for PAGN formation, but it correlates with ammonia control, it is often used as a dosing biomarker, and its intracellular accumulation in glial cells is believed to be one of the factors responsible for cerebral edema, a potentially lethal complication in UCD.12, 13, 14

These encouraging biochemical findings in short-term studies were corroborated by the findings in the long-term follow-up studies, which included ∼40% fewer hyperammonemic crises and improvement in executive functioning among pediatric patients, for whom mean fasting ammonia averaged approximately half the ULN. These changes in executive function are of particular interest, as problems with behavioral regulation, planning, monitoring progress, purposeful problem solving, etc., are known to compromise the day-to-day function of UCD patients including those with normal IQ.3, 4 While necessarily uncontrolled, the absence of change in other neuropsychological test scores during the 12 months of treatment, particularly the CBCL, which is a parent report measure of the child's functioning in their day-to-day environment, suggests that these improvements in executive function do not represent a placebo response. Moreover, the improvement in executive function while taking GPB suggests that UCD patients exhibit neuropsychological abnormalities that may be reversible with effective treatment.

Finally, as a result of the significant barriers to conducting randomized, placebo-controlled trials in rare disorders, the treatment of inborn errors of metabolism is often based on experience and expert opinion.15, 16 The present findings demonstrate that with effective public-private cooperation, rigorously controlled clinical trials are possible even in ultra-rare genetic diseases.

Acknowledgements

  1. Top of page
  2. Abstract
  3. Materials and Methods
  4. Results
  5. Discussion
  6. Acknowledgements
  7. References

The authors thank the efforts of the Study Coordinators and nursing staff who made these trials possible, including N. Schrager (Mount Sinai School of Medicine), A. Donovan, J. Crawford, Pediatric TRU Staff, K. Defouw, J. Balliet (The Medical College of Wisconsin), M. Keuth, N. O'Donnell (Long Beach Memorial Hospital), M. Hussain, E. Bailey, A. Orton, M. Ambreen (The Hospital for Sick Children, University of Toronto, ON, Canada), C. Bailey, A. Lang (The University of Utah), J. Perry, V. de Leon, A. Niemi, K. Cusmano (Stanford University), T. Carlson, J. Parker (University of Minnesota), S. Burr (Children's Hospital Colorado), K. Simpson (Children's National Medical Center), K. Regis (Nationwide Children's Hospital), A. Behrend, T. Marrone (Oregon Health Sciences University), N. Dorrani (University of California, Los Angeles), C. Heggie (Case Western Reserve University), S. Mortenson (Maine Medical Center), S. Deward (Children's Hospital of Pittsburgh), K. Bart, C. Duggan (SNBL), K. Murray, C. Dedomenico (Tufts Medical Center), C. Gross (University of Florida), L. Brody (Seattle Children's Hospital), M. Mullins, S. Carter, A. Tran, J. Stuff, TCH General Clinical Research Center nursing staff (Baylor), and Kathy Lisam (Hyperion).

References

  1. Top of page
  2. Abstract
  3. Materials and Methods
  4. Results
  5. Discussion
  6. Acknowledgements
  7. References
  • 1
    Enns GM, Berry SA, Berry GT, Rhead WJ, Brusilow SW, Hamosh A. Survival after treatment with phenylacetate and benzoate for urea cycle disorders. N Engl J Med 2007; 356: 2282-2292.
  • 2
    Lampher BC, Gropman A, Chapman KA, Lichter-Konecki U, Urea Cycle Disorder Consortium, Summar ML. Urea cycle disorders overview. 2012. http://www.ncbi.nlm.nih.gov/books/NBK1217/
  • 3
    Gropmann A, Fricke S, Seltzer RR, Hailu A, Adeyemo A, Sawyer A, et al. 1H MRS identifies symptomatic and asymptomatic patients with partial ornithine transcrbamylase deficiency. Mol Gen and Metab 2008; 95: 21-30.
  • 4
    Krivitzky L, Babikian T, Lee HS, Thomas NH, Burk-Paull KL, Batshaw ML. Intellectual, adaptive, and behavioral functioning in children with urea cycle disorders. Pediatr Res 2009; 66: 96-101.
  • 5
    Brusilow SW. Phenylacetylglutamine may replace urea as a vehicle for waste nitrogen excretion. Pediatr Res 1991; 29: 147-150.
  • 6
    Lee B, Rhead W, Diaz GA, Scharschmidt BF, Mian A, Shchelochkov O, et al. Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: safety, pharmacokinetics and ammonia control. Mol Genet Metab 2010; 100: 221-228.
  • 7
    McGuire BM, Zupanets IA, Lowe ME, Xiao X, Syplyviy VA, Monteleone J, et al. Pharmacology and safety of glycerol phenylbutyrate in healthy adults and adults with cirrhosis. HEPATOLOGY 2010; 51: 2077-2085.
  • 8
    Lichter-Konecki U, Diaz GA, Merritt JLII, Feigenbaum A, Jomphe C, Marier JF, et al. Ammonia control in children with urea cycle disorders (UCDs); Phase 2 comparison of sodium phenylbutyrate and glycerol phenylbutyrate. Mol Genet Metab 2011; 103: 323-329.
  • 9
    Seminara J, Tuchman M, Krivitzky L, Krischer J, Lee HS, LeMons C, et al. Establishing a consortium for the study of rare diseases: the Urea Cycle Disorders Consortium. Mol Genet Metab 2010; 100( S1): S97-S105
  • 10
    National Urea Cycles Disorder Foundation. 2012;http://www.nucdf.org/
  • 11
    Gioia GA, Isquith PK, Guy SC, Kenworthy L. Behavior rating inventory of executive function. Lutz, FL: Psychological Assessment; 2000 (original version), 2003 (preschool version), 2005 (adult version).
  • 12
    Butterworth RF, Norenberg MD, Felipo V, Ferenci P, Albrecht J, Blei AT. Members of the ISHEN Commission on Experimental Models of HE. Experimental models of hepatic encephalopathy: ISHEN guidelines. Liver Int 2009; 29: 783-788.
  • 13
    Maestri NE, McGowan KD, Brusilow SW. Plasma glutamine concentration: a guide in the management of urea cycle disorders. J Pediatr 1992; 121: 259-261.
  • 14
    Tuchman M, Lee B, Lichter-Konecki U, Summar ML, Yudkoff M, Cederbaum SD, et al., Urea Cycle Disorders Consortium of the Rare Diseases Clinical Research Network. Cross-sectional multicenter study of patients with urea cycle disorders in the United States. Mol Genet Metab 2008; 94: 397-402.
  • 15
    Kerr DS. Treatment of mitochondrial electron transport chain disorders: a review of clinical trials over the past decade. Mol Genet Metab 2010; 99: 246-255.
  • 16
    Vockley J, Vockley CM. Clinical trials: curing a critical deficiency in metabolic medicine. Mol Genet Metab 2010; 99: 244-245.